Core--ES Cell and Microinjection Facility

核心--ES细胞及显微注射设备

• 批准号: 7071812
• 负责人: MICHAEL J SCHNEIDER
• 金额: $ 16.81万
• 依托单位: TEXAS A&M UNIVERSITY HEALTH SCIENCE CTR
• 依托单位国家: 美国
• 资助国家: 美国
• 起止时间: 至
• 项目状态: 未结题
• 来源: https://reporter.nih.gov/project-details/7071812
• 关键词: biomedical facility; cardiogenesis; developmental genetics; embryonic stem cell; genetically modified animals; laboratory mouse; mammalian embryology; microinjections; tissue mosaicism

The component studies in this Program Project on the genetics of early cardiac development share a technical and biological focus on the mouse as the organism studied. Among vertebrates, only the mouse permits so robust a range of genetic manipulations. The projects involve creating mutations in the germ line and somatic tissues of mice by performing homologous recombination in ES cells, or Cre/IoxP recombination in vivo. Other needs include the creation of mice harboring a bacterial artificial chromosome (BAC), conventional transgene, inducible transgene, or engineered cells that are introduced into blastocysts. These procedures for manipulation of ES cells and the construction of mice are technically demanding and most efficiently performed in a dedicated core laboratory. All of these alleles and technologies have been successfully implemented by the Core Directors, and many of the specific innovations were developed through prior support of this Project.

该项目中关于早期心脏发育遗传学的组成部分研究在技术和生物学上都以小鼠为研究对象。在脊椎动物中，只有小鼠能够进行如此强大的一系列基因操作。这些项目涉及通过在 ES 细胞中进行同源重组或在体内进行 Cre/IoxP 重组，在小鼠的种系和体细胞组织中产生突变。其他需求包括培育携带细菌人工染色体 (BAC)、传统转基因、诱导型转基因或引入囊胚的工程细胞的小鼠。这些操作 ES 细胞和构建小鼠的程序技术要求很高，并且在专门的核心实验室中执行效率最高。所有这些等位基因和技术均已由核心董事成功实施，并且许多具体创新都是通过该项目的事先支持而开发的。